Long-Term Deutetrabenazine Treatment for Tardive Dyskinesia Is Associated With Sustained Benefits and Safety: A 3-Year, Open-Label Extension Study

BackgroundDeutetrabenazine is a vesicular monoamine transporter 2 inhibitor approved for the treatment of tardive dyskinesia (TD) in adults. In two 12-week pivotal studies, deutetrabenazine demonstrated statistically significant improvements in Abnormal Involuntary Movement Scale (AIMS) scores, with...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Robert A. Hauser, Hadas Barkay, Hubert H. Fernandez, Stewart A. Factor, Joohi Jimenez-Shahed, Nicholas Gross, Leslie Marinelli, Amanda Wilhelm, Jessica Alexander, Mark Forrest Gordon, Juha-Matti Savola, Karen E. Anderson
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Frontiers Media S.A. 2022-02-01
Saila:	Frontiers in Neurology
Gaiak:	deutetrabenazine efficacy safety tardive dyskinesia treatment
Sarrera elektronikoa:	https://www.frontiersin.org/articles/10.3389/fneur.2022.773999/full
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!